Animesh Pardanani

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition

Omar Abdel-Wahab, Qiong Yang, Ayalew Tefferi, 2015, Nature Medicine.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Catriona Jamieson, Ayalew Tefferi, Moshe Talpaz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AKT is a therapeutic target in myeloproliferative neoplasms

Qiang Wen, Ayalew Tefferi, Ross L. Levine, 2013, Leukemia.

Myeloproliferative Neoplasms A Contemporary Review

Ayalew Tefferi, A. Tefferi, A. Pardanani, 2015 .

Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.

Ayalew Tefferi, A. Tefferi, A. Pardanani, 2004, Blood.

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

D. Gary Gilliland, Ayalew Tefferi, Ross L. Levine, 2007, Nature Reviews Cancer.